Daily Respiratory Research Analysis
Analyzed 193 papers and selected 3 impactful papers.
Summary
Three impactful studies advance respiratory medicine: (1) innate TLR3/type I interferon variability robustly predicts mRNA COVID-19 vaccine responses and is linked to a common TLR3 polymorphism; (2) early outpatient oral antivirals are associated with a reduced risk of post‑COVID‑19 condition; and (3) AI models using overnight pulse oximetry achieve high diagnostic accuracy for obstructive sleep apnoea, supporting scalable screening.
Research Themes
- Innate immune predictors of vaccine efficacy
- Early antiviral therapy to mitigate long-term COVID-19 sequelae
- AI-enabled, low-cost diagnostics for sleep-disordered breathing
Selected Articles
1. Variability in the TLR3 type I interferon pathway is predictive of RNA vaccine responses.
Prevaccine TLR3-driven IFN-I responses strongly predict mRNA vaccine T-cell cytokine and antibody responses, replicated in an independent cohort of 990 donors. A common TLR3 polymorphism modulates IFN-I induction and downstream vaccine-specific T-cell responses, highlighting an innate pathway for vaccine tailoring.
Impact: This study links innate immune variability and genetics to vaccine immunogenicity across multiple cohorts, offering a mechanistic basis to stratify and optimize mRNA vaccination.
Clinical Implications: Prevaccine immune phenotyping could inform personalized vaccine strategies and adjuvant selection, especially in populations with blunted IFN-I responses or specific TLR3 genotypes.
Key Findings
- Prevaccine poly(I:C)-induced IFN-I responses significantly associated with postvaccine T-cell cytokine responses.
- BNT162b2 recipients showed higher antigen-specific IL-2, IFN-γ, IL-21, antibody levels, and pseudo-neutralization than CoronaVac.
- Independent validation (n=990) confirmed association between poly(I:C)-induced IFN-α and spike-induced cytokines in mRNA vaccinees.
- A common TLR3 polymorphism influenced IFN-I induction and vaccine-specific T-cell responses.
Methodological Strengths
- Multi-cohort design with independent validation (including n=990 donors).
- Integrated protein and transcriptomic readouts following standardized TLR agonist stimulation.
Limitations
- Observational associations cannot prove causality for clinical protection.
- Heterogeneity between vaccine platforms may confound comparative immunogenicity.
Future Directions: Prospective interventional studies modulating TLR3/IFN-I pathways to enhance vaccine responses; evaluation across age groups and immunocompromised populations.
Biological predictors of variable vaccine responses are lacking. We hypothesized that variability in prevaccine innate immune responses, specifically for type I interferons (IFN-I), is predictive of postvaccine antigen-specific responses. To test this, we assessed prevaccine immune responses at protein and transcriptomic levels following whole blood stimulation with Toll-like receptor (TLR) viral agonists in healthy adolescents and adults. Four weeks after the second vaccine dose, with either the BNT162b2 mRNA or CoronaVac inactivated virus vaccine, we assessed antigen-specific T cell cytokine responses and plasma antibody levels. BNT162b2 vaccinees had increased production of the antigen-specific T cell cytokines interleukin-2 (IL-2), interferon-γ, and IL-21 after severe acute respiratory syndrome coronavirus 2 spike stimulation, as well as increased antibody levels and serum pseudo-neutralization compared with CoronaVac recipients. In direct support of our hypothesis, we find that prevaccine poly(I:C) (polyinosine-polycytidylic acid; TLR3 viral agonist) IFN-I responses were significantly associated with the postvaccine T cell cytokine responses. In an independent cohort of 990 healthy donors, we confirmed the significant association between poly(I:C)-induced IFN-α and spike-induced cytokines in mRNA vaccine recipients. We further confirmed this specific association in a cohort of healthy Europeans and identified a common genetic polymorphism in TLR3 that affects IFN-I induction and subsequent vaccine-specific T cell responses. This study shows that preexisting innate immune variability can predict the effectiveness of vaccine responses and identifies pathways relevant to mRNA vaccination. Targeting the specific innate immune pathway relevant for a vaccine may provide a new approach for tailoring vaccines to different populations.
2. Early-Phase Oral Antiviral Use and Post-COVID-19 Condition in Outpatients.
In 7,699 outpatients, early oral antivirals were associated with a lower risk of PCC (adjusted RR 0.86, 95% CI 0.78–0.93) and fewer failures to return to usual health by day 84 (aRR 0.77, 95% CI 0.67–0.89). Effects were consistent across agents including ensitrelvir and molnupiravir.
Impact: Large, prospective, nationwide cohort links timely antiviral therapy to reduced long-COVID risk in community patients, informing outpatient treatment policies.
Clinical Implications: Encourages prompt initiation of oral antivirals in eligible outpatients to potentially reduce PCC risk and expedite return to baseline health.
Key Findings
- Among 7,699 outpatients, early oral antivirals were associated with lower PCC risk (aRR 0.86; 95% CI 0.78–0.93).
- Ensitrelvir (aRR 0.86; 95% CI 0.79–0.95) and molnupiravir (aRR 0.81; 95% CI 0.67–0.98) showed consistent associations.
- Failure to return to usual health by day 84 was reduced (9.9% vs 12.9%; aRR 0.77; 95% CI 0.67–0.89).
Methodological Strengths
- Prospective, nationwide, multicenter registry with prespecified covariate adjustment.
- Large sample size during Omicron sublineages with standardized follow-up at days 28 and 84.
Limitations
- Observational design subject to residual confounding and indication bias despite adjustment.
- Antiviral selection was not randomized; agent-specific effects may reflect prescribing patterns.
Future Directions: Randomized or quasi-experimental designs to confirm causality; stratified analyses by variant, timing, comorbidities, and specific antiviral agents.
IMPORTANCE: Post-COVID-19 condition (PCC) contributes substantially to long-term morbidity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Information about the effectiveness of oral antivirals in preventing PCC in outpatient populations remains limited. OBJECTIVE: To evaluate the association between early oral antiviral use and PCC risk among outpatients with COVID-19, with and without risk factors for severe disease. DESIGN, SETTING, AND PARTICIPANTS: Prospective, nationwide, multicenter, registry-based cohort study conducted at 51 acute-care hospitals across Japan during the predominance of Omicron sublineages JN.1 and KP.3. Outpatients aged 12 years or older with laboratory-confirmed COVID-19, symptom onset of 5 days or less before enrollment, and no recent anti-SARS-CoV-2 treatment were enrolled between February and October 2024, with follow-up through February 2025. The primary analysis population included participants with complete baseline covariates and valid day 28 and day 84 assessments. EXPOSURES: Oral antiviral use (ensitrelvir, nirmatrelvir, or molnupiravir) at enrollment vs no antiviral use. MAIN OUTCOMES AND MEASURES: The primary outcome was PCC, defined as persistence of...
3. Artificial Intelligence Diagnosis of Obstructive Sleep Apnoea using Overnight Pulse Oximetry: A Systematic Review and Bayesian Meta-Analysis.
Across 25 studies (23,171 participants), AI-oximetry achieved pooled sensitivity 91.1% (95% CrI 89.7–92.4%) and specificity 88.4% (95% CrI 85.3–90.8%). Neural networks performed best; deep learning feature extraction improved sensitivity by 3.7% over expert-engineered features. Accuracy was robust across AHI cut-offs, supporting scalable OSA screening.
Impact: Provides the first rigorous pooled accuracy estimate for AI models using only oximetry, indicating near–home-based diagnostic potential with strong performance.
Clinical Implications: Supports deployment of AI-oximetry as a triage or diagnostic tool in primary care and inpatient settings to expand OSA detection where PSG access is limited.
Key Findings
- Pooled sensitivity 91.1% and specificity 88.4% with DOR 77.7 across 23,171 participants.
- Neural networks had highest sensitivity (92.7%) and specificity (91.3%).
- Deep learning feature extraction increased sensitivity by 3.7% over expert-engineered features.
- Specificity increased with higher AHI thresholds; publication bias analyses showed robust accuracy.
Methodological Strengths
- Pre-registered (PROSPERO) Bayesian bivariate meta-analysis with QUADAS-2 and GRADE assessments.
- Large aggregated sample with model class meta-regression and sensitivity analyses for publication bias.
Limitations
- Heterogeneity in AI architectures, datasets, and AHI thresholds across studies.
- Limited prospective external validation in low-prevalence, real-world primary care cohorts.
Future Directions: Prospective, multi-center clinical validation and cost-effectiveness studies integrating AI-oximetry into care pathways and home-based screening.
BACKGROUND: Obstructive sleep apnoea (OSA) affects 38% of the population, yet over 90% of cases remain undiagnosed. The current gold standard for diagnosis, polysomnography (PSG), requires specialised equipment, and trained personnel, making it inaccessible in primary care and acute settings. With AI advancements, oximetry-based AI models have emerged as a potential alternative for OSA diagnosis. OBJECTIVE: This meta-analysis aims to evaluate the diagnostic accuracy of AI models trained on pulse oximetry readings in diagnosing OSA. METHODS: A systematic search was conducted across Medline/PubMed, Embase, Scopus, Web of Science, and IEEE Xplore databases from inception to 3 January 2026. Studies that evaluated the diagnostic accuracy of AI models trained on SpO₂ recordings, compared to the apnoea-hypopnea index (AHI) as the reference standard were included and screened by two blinded independent reviewers...